Laboratorios Farmaceuticos Rovi, S.A. (FRA:41L)

Market Cap	4.34B +77.0%
Revenue (ttm)	743.48M -2.7%
Net Income	140.44M +2.6%
EPS	2.75 +2.7%
Shares Out	n/a
PE Ratio	30.92
Forward PE	27.67
Dividend	0.76 (0.89%)
Ex-Dividend Date	Jul 14, 2025

Volume	n/a
Average Volume	29
Open	84.30
Previous Close	85.00
Day's Range	84.30 - 84.30
52-Week Range	50.05 - 85.65
Beta	n/a
RSI	63.03
Earnings Date	May 6, 2026

About FRA:41L

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Expr...

• Industry: Pharmaceutical Preparations
• Founded: 1946
• Employees: 1,998
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 41L

Financial Performance

In 2025, FRA:41L's revenue was 743.48 million, a decrease of -2.65% compared to the previous year's 763.75 million. Earnings were 140.44 million, an increase of 2.60%.